Literature DB >> 26799257

Molecular targeting of papillary thyroid carcinoma with fluorescently labeled ratiometric activatable cell penetrating peptides in a transgenic murine model.

Ryan K Orosco1, Elamprakash N Savariar2, Philip A Weissbrod1, Julio A Diaz-Perez3, Michael Bouvet4, Roger Y Tsien2,5, Quyen T Nguyen1.   

Abstract

BACKGROUND AND OBJECTIVES: Molecularly targeted fluorescent molecules may help detect tumors that are unseen by traditional white-light surgical techniques. We sought to evaluate a fluorescent ratiometric activatable cell penetrating peptide (RACPP) for tumor detection in a transgenic model of PTC.
METHODS: Thirteen BRAFV600E mice with PTC were studied-seven injected intravenously with RACPP, four controls with saline. Total thyroidectomy was performed with microscopic white-light visualization. Fluorescent imaging of post-thyroidectomy fields was performed, and tissue with increased signal was removed and evaluated for PTC. Final samples were analyzed by a pathologist blinded to conditions. Vocal cord function was evaluated postoperatively with video laryngoscopy.
RESULTS: The average in situ ratiometric (Cy5/Cy7) thyroid tumor-to-background contrast ratio was 2.27 +/- 0.91. Fluorescence-guided clean-up following thyroidectomy identified additional tumor in 2 of 7 RACPP animals (smallest dimension 1.2 mm), and decreased the number of animals with residual tumor from 4 to 3. All retained tumor foci on final pathology were smaller than 0.76 mm. Intact vocal abduction was present in all of the RACPP animals.
CONCLUSIONS: RACPPs successfully targeted PTC in a transgenic thyroidectomy model, and allowed for residual tumor detection that reduced positive margins beyond what was possible with white-light surgery alone.
© 2016 Wiley Periodicals, Inc.

Entities:  

Keywords:  BRAF V600E; activatable cell penetrating peptide; laryngoscopy; murine model; papillary thyroid cancer; surgical molecular guidance

Mesh:

Substances:

Year:  2016        PMID: 26799257      PMCID: PMC4986916          DOI: 10.1002/jso.24129

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN: 0022-4790            Impact factor:   3.454


  30 in total

1.  Surgical method to create vocal fold injuries in mice.

Authors:  Masaru Yamashita; Diane M Bless; Nathan V Welham
Journal:  Ann Otol Rhinol Laryngol       Date:  2009-02       Impact factor: 1.547

2.  Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer.

Authors:  David S Cooper; Gerard M Doherty; Bryan R Haugen; Bryan R Hauger; Richard T Kloos; Stephanie L Lee; Susan J Mandel; Ernest L Mazzaferri; Bryan McIver; Furio Pacini; Martin Schlumberger; Steven I Sherman; David L Steward; R Michael Tuttle
Journal:  Thyroid       Date:  2009-11       Impact factor: 6.568

3.  The association of the BRAF(V600E) mutation with prognostic factors and poor clinical outcome in papillary thyroid cancer: a meta-analysis.

Authors:  Tae Hyuk Kim; Young Joo Park; Jung Ah Lim; Hwa Young Ahn; Eun Kyung Lee; You Jin Lee; Kyung Won Kim; Seo Kyung Hahn; Yeo Kyu Youn; Kwang Hyun Kim; Bo Youn Cho; Do Joon Park
Journal:  Cancer       Date:  2011-08-31       Impact factor: 6.860

4.  Tumor imaging by means of proteolytic activation of cell-penetrating peptides.

Authors:  Tao Jiang; Emilia S Olson; Quyen T Nguyen; Melinda Roy; Patricia A Jennings; Roger Y Tsien
Journal:  Proc Natl Acad Sci U S A       Date:  2004-12-15       Impact factor: 11.205

5.  Long-term results of treatment of 283 patients with lung and bone metastases from differentiated thyroid carcinoma.

Authors:  M Schlumberger; M Tubiana; F De Vathaire; C Hill; P Gardet; J P Travagli; P Fragu; J Lumbroso; B Caillou; C Parmentier
Journal:  J Clin Endocrinol Metab       Date:  1986-10       Impact factor: 5.958

6.  Mutational profile of advanced primary and metastatic radioactive iodine-refractory thyroid cancers reveals distinct pathogenetic roles for BRAF, PIK3CA, and AKT1.

Authors:  Julio C Ricarte-Filho; Mabel Ryder; Dhananjay A Chitale; Michael Rivera; Adriana Heguy; Marc Ladanyi; Manickam Janakiraman; David Solit; Jeffrey A Knauf; R Michael Tuttle; Ronald A Ghossein; James A Fagin
Journal:  Cancer Res       Date:  2009-06-01       Impact factor: 12.701

7.  Clinicopathologic significance of BRAF V600E mutation in papillary carcinomas of the thyroid: a meta-analysis.

Authors:  Ju-Han Lee; Eung-Seok Lee; Young-Sik Kim
Journal:  Cancer       Date:  2007-07-01       Impact factor: 6.860

8.  BRAF mutation testing of thyroid fine-needle aspiration biopsy specimens for preoperative risk stratification in papillary thyroid cancer.

Authors:  Mingzhao Xing; Douglas Clark; Haixia Guan; Meiju Ji; Alan Dackiw; Kathryn A Carson; Matthew Kim; Anthony Tufaro; Paul Ladenson; Martha Zeiger; Ralph Tufano
Journal:  J Clin Oncol       Date:  2009-05-04       Impact factor: 44.544

9.  Real-time in vivo molecular detection of primary tumors and metastases with ratiometric activatable cell-penetrating peptides.

Authors:  Elamprakash N Savariar; Csilla N Felsen; Nadia Nashi; Tao Jiang; Lesley G Ellies; Paul Steinbach; Roger Y Tsien; Quyen T Nguyen
Journal:  Cancer Res       Date:  2012-11-27       Impact factor: 12.701

10.  Enhanced activation of matrix metalloproteinase-9 correlates with the degree of papillary thyroid carcinoma infiltration.

Authors:  Ilona Marecko; Dubravka Cvejic; Sonja Selemetjev; Svetlana Paskas; Svetislav Tatic; Ivan Paunovic; Svetlana Savin
Journal:  Croat Med J       Date:  2014-04       Impact factor: 1.351

View more
  3 in total

Review 1.  Advances in fluorescent-image guided surgery.

Authors:  Mark J Landau; Daniel J Gould; Ketan M Patel
Journal:  Ann Transl Med       Date:  2016-10

2.  Biological Evaluation of a Fluorescent-Imaging Agent for Medullary Thyroid Cancer in an Orthotopic Model.

Authors:  Kara K Rossfeld; Steven E Justiniano; Haiming Ding; Li Gong; Shankaran Kothandaraman; Dwitiya Sawant; Motoyasu Saji; Chadwick L Wright; Lawrence S Kirschner; Matthew D Ringel; Michael F Tweedle; John E Phay
Journal:  J Clin Endocrinol Metab       Date:  2017-09-01       Impact factor: 5.958

Review 3.  Preclinical Imaging for the Study of Mouse Models of Thyroid Cancer.

Authors:  Adelaide Greco; Luigi Auletta; Francesca Maria Orlandella; Paola Lucia Chiara Iervolino; Michele Klain; Giuliana Salvatore; Marcello Mancini
Journal:  Int J Mol Sci       Date:  2017-12-16       Impact factor: 5.923

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.